ORMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Oramed Pharmaceuticals Inc (ORMP) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are neutral to slightly bearish, the options sentiment is not strongly bullish, and the financial performance shows significant declines in net income and EPS. Additionally, there are no recent positive news catalysts or significant trading activity from insiders or politicians to support a buy decision.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 29.502, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 3.337, with key support at 3.191 and resistance at 3.483.
NULL. No recent news, insider activity, or significant trading trends to act as a positive catalyst.
The company's financial performance for Q3 2025 shows a significant decline in net income (-346.67% YoY) and EPS (-335.42% YoY), which are major red flags for long-term investors.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly to -$48.4M (-346.67% YoY), and EPS fell to -1.13 (-335.42% YoY). Gross margin increased slightly to 0.65, but this is not enough to offset the poor overall performance.
No recent analyst ratings or price target changes available.
